Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Joris Wilms Sells 5,000 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Joris Wilms sold 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $15.17 on Wednesday. The stock’s 50-day moving average price is $12.12 and its two-hundred day moving average price is $13.74. Y-mAbs Therapeutics, Inc. has a 1 year low of $4.69 and a 1 year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The company had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period in the prior year, the company earned ($0.14) EPS. On average, research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its position in Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Squarepoint Ops LLC raised its position in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares in the last quarter. XTX Topco Ltd bought a new stake in Y-mAbs Therapeutics during the second quarter worth $297,000. Dimensional Fund Advisors LP increased its stake in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Y-mAbs Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after purchasing an additional 2,760 shares during the period. 70.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

YMAB has been the topic of several research reports. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, August 12th. Morgan Stanley lowered their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics in a report on Friday, August 16th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 target price on the stock. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.